Skip to main content
Premium Trial:

Request an Annual Quote

Locus Pharmaceuticals To Use Invitrogen s SelectScreen Platform

NEW YORK, May 16 (GenomeWeb News) - Invitrogen will provide Locus Pharmaceuticals with kinase screening services through its SelectScreen platform, Invitrogen said today.

 

Invitrogen said that the platform will support Locus' discovery programs in the areas of cancer and inflammation.

 

Financial details of the transaction were not disclosed.

 

Invitrogen said that it has added 123 new human protein kinases to its SelectScreen screening panel over the last 14 months and that it will continue to expand the panel this year.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.